IVMP

DRUG3 trials

Sponsors

Feng Jinzhou, Tianjin Medical University General Hospital, Chinese PLA General Hospital

Conditions

EfgartigimodNeuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder Attack

Phase 2

Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder

WithdrawnNCT06673394

Tianjin Medical University General HospitalNeuromyelitis Optica Spectrum Disorder Attack

Start: 2025-09-03End: 2026-12-01Updated: 2025-09-10

Phase 4

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

RecruitingNCT07410039

Chinese PLA General HospitalNeuromyelitis Optica Spectrum Disorder Attack

Start: 2026-02-01End: 2029-06-30Target: 200Updated: 2026-03-12

Unknown Phase

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

Feng JinzhouEfgartigimod, Neuromyelitis Optica

Start: 2023-11-05End: 2025-05-05Target: 24Updated: 2023-11-07